Digital Cognitive Task Matches or Exceeds Benchmarks for Alzheimer's Trials
Cumulus Neuroscience's brief digital task demonstrated the ability to match or outperform clinical benchmarks for identifying Alzheimer's disease pathology and discriminating between patient groups.
London, July 15, 2026 – Cumulus Neuroscience presented data from its new digital cognitive task at the Alzheimer's Association International Conference 2026. The company's NeuLogiq platform's Symbol Swap task, a two-minute tablet-based assessment, successfully discriminated between control groups, individuals with mild cognitive impairment (MCI), and those with Alzheimer's dementia.
Across three independent studies, the Symbol Swap task's performance matched or exceeded that of established clinical cognitive screening tests like ADAS-Cog, MoCA, and MMSE, which typically take 10 to 45 minutes to administer. The task also identified Alzheimer's pathology, as defined by blood biomarkers, even in cognitively normal individuals, suggesting its potential for more efficient risk stratification.
The digitally administered and automatically scored Symbol Swap task holds the potential to significantly enhance the efficiency of Alzheimer's clinical trials. It is expected to accelerate recruitment and reduce screening failures, potentially shortening the development timeline for new therapies and lowering costs.
Cumulus Neuroscience also presented a second poster related to the NeuLogiq platform, focusing on decentralized Alzheimer's trials. This study indicated that digital cognitive and EEG measures were well-tolerated and sensitive enough to capture meaningful changes, enabling the design of smaller, more cost-effective trials.